Added to YB: 2025-09-08
Pitch date: 2025-09-04
MXCT [bullish]
MaxCyte, Inc.
+12.59%
current return
Author Info
Two Natural Capital writes about markets, particularly focused on life sciences/biotech. Sign up for the newsletter.
Company Info
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
Market Cap
$168.5M
Pitch Price
$1.35
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.87
P/E
-3.67
EV/Sales
2.35
Sector
Life Sciences Tools and Services
Category
value
MaxCyte: Powering Ex-Vivo Gene Editing $mxct
MXCT: Electroporation instruments/consumables for ex-vivo non-viral cell therapies, powers FDA-approved Casgevy CRISPR treatment. Supplies CRISPR Therapeutics, Beam, Sana. 80%+ margins, SPL royalty agreements. Stock down 90% from 2021 IPO, 0.75x P/B ratio, no debt. Bull case: allogeneic CAR-T breakthrough. Bear case: treatments fail or competitors take share.
Read full article (6 min)